Glutathione (Skin Whitening)
γ-L-glutamyl-L-cysteinylglycine
Antioxidant tripeptide hyped for brightening; weak evidence, risky IV use
Evidence tier
Preliminary
Research weight
Citations
18 verified / 18
Classification
Joint & Skin
❝
What the evidence says. Early or small human trials; promising but not yet conclusive.
⚠
Health warning. Intravenous glutathione for skin whitening is not approved for this use, and regulators (Philippine FDA, US FDA) warn it can cause serious harm including Stevens-Johnson syndrome and organ toxicity.
What is Glutathione (Skin Whitening)?
Glutathione (Skin Whitening) (γ-L-glutamyl-L-cysteinylglycine) is a joint and skin supplement used for may modestly, temporarily reduce skin melanin (oral, small trials). NutriDex grades the human evidence as Preliminary. Glutathione is a naturally occurring tripeptide antioxidant that can inhibit melanin synthesis via the tyrosinase pathway, which is why it is marketed for skin lightening. However, oral glutathione is poorly absorbed (largely degraded in the gut), and the human evidence rests on a few small, short trials showing modest, transient reductions in melanin index; larger and combination trials often failed to reach significance. The bigger concern is intravenous glutathione for whitening, sold off-label with no validated dosing or convincing efficacy. Regulators including the Philippine FDA and US FDA warn that injectable glutathione for skin lightening is unapproved and linked to serious harms.
Purported Benefits
✓May modestly, temporarily reduce skin melanin (oral, small trials)
✓Claimed 'brightening' (marketing, not robustly proven)
✓Antioxidant that inhibits tyrosinase/melanin in vitro
Evidence by outcome
The same supplement can be well-proven for one use and unproven for another — here is the human evidence graded outcome by outcome.
| Outcome | Evidence | Effect | Studies |
|---|---|---|---|
| Skin lightening / reduced melanin index (oral)Several small RCTs and systematic reviews show modest melanin-index drops, but effects are unsustained and several trials missed significance. | Mixed | ↔ mixed · small | 5 |
| Skin lightening (intravenous)No published efficacy trials for IV whitening; regulators flag serious harms (endotoxin poisoning, SJS/TEN, hepatotoxicity). | No Evidence | — no effect | 3 |
| Reduced UV spots / wrinkles (secondary skin aging)One RCT found GSH reduced wrinkles at some sites; UV-spot trends were inconsistent and often non-significant. | Preliminary | ↔ mixed · small | 2 |
Dosing & Compounds
Typical Dose
Studied oral doses ~250–500 mg/day for 4–12 weeks; IV/injectable is the dangerous off-label whitening route.
Active Compounds
Safety & Cautions
Oral glutathione at studied doses appears well tolerated short-term, but long-term cosmetic safety is unestablished and absorption is poor. The major danger is IV/injectable glutathione for whitening: NOT approved for this purpose, lacking validated dosing, and linked to severe skin reactions (SJS, TEN), anaphylaxis, hepatotoxicity, and renal/thyroid effects, plus infection from non-sterile 'drip' settings. Any lightening is temporary and reverses on stopping. Avoid IV glutathione for cosmetic whitening. Educational only — always check with your doctor or pharmacist before combining Glutathione (Skin Whitening) with any medicine.
Key Studies ★ 18 studies
systematic review
Sarkar 2025 (systematic review)
✓ Full text
Systematic review (PubMed/Embase/Cochrane); across 5 RCTs plus 1 open-arm study, oral glutathione 250 mg once/twice daily or 500 mg/day significantly reduced the melanin index vs placebo, with topical 0.5% > 0.1% > placebo, but effects were modest and unsustained.
systematic review
Khanna 2025 (systematic review)
✓ PubMed
Systematic review of topical glutathione in dermatology found 2% oxidized glutathione lotion significantly lowered melanin index (p<0.05) in a 30-woman split-face trial and a combination cream reduced melanin index at 8 weeks, but evidence base remains small.
Systematic review
Khanna 2025
✓ Full text
Systematic review of five clinical trials of topical glutathione found a 2% oxidized glutathione lotion significantly lowered melanin index from 272.77 +/- 26.17 at week 0 to 243.47 +/- 26.31 at week 10 (p<0.05), with effects localized to treated/sun-exposed skin.
Systematic review
Sarkar et al. 2025 (Int J Dermatol)
✓ PubMed
Systematic review of glutathione for skin-lightening/melasma: five RCTs plus one open-arm study of ORAL glutathione (250 mg once daily, 250 mg twice daily, and 500 mg once daily) showed a significant reduction in melanin index vs placebo; topical 2% plus oral combination was superior to monotherapy. Concluded oral/topical glutathione gives only moderate, unsustainable lightening, while IV glutathione is contraindicated (lack of efficacy and side effects).
Systematic review
Dilokthornsakul et al. 2019 (J Cosmet Dermatol)
✓ PubMed
Systematic review (4 studies; 3 placebo-controlled RCTs, 1 single-arm) found oral glutathione 500 mg/day (and topical 2.0% oxidized glutathione) significantly brightened skin in sun-EXPOSED areas by melanin index, with a trend toward improved wrinkles, elasticity and fewer UV spots; no significant effect in sun-protected areas. Concluded overall evidence is inconclusive due to study quality and inconsistency.
Agency / regulator
Philippine FDA Advisory 2019-182
✓ Source
Warns injectable glutathione for skin lightening is not approved for this use and risks Stevens-Johnson syndrome, toxic epidermal necrolysis, and thyroid/liver/kidney/nervous-system toxicity.
regulatory
US FDA Compounding Concern (2019)
✓ Source
FDA warning that dietary-supplement-grade L-glutathione powder is unsuitable for compounding sterile injectables; seven patients given an L-glutathione-compounded IV product (200 mg/mL) had adverse events from excessive endotoxins ranging from nausea/vomiting to difficulty breathing, with one hospitalization, and no injectable glutathione is FDA-approved.
randomized controlled trial
Sitohang 2021 (RCT)
✓ PubMed
Indonesian multicenter double-blind RCT (n=83 completed) of oral glutathione 500 mg plus ascorbic acid/alpha-lipoic acid/zinc over 12 weeks vs placebo; reductions in spot-UV, spot-polarization, and skin tone were greater with glutathione but not statistically significant.
randomized controlled trial
Duperray 2022 (RCT)
✓ Full text
12-week double-blind, placebo- and benchmark-controlled RCT in 124 Asian women; oral 500 mg L-cystine plus 250 mg reduced L-glutathione significantly lightened dark spots versus glutathione alone, cystine alone, and placebo.
RCT
Wahab et al. 2021 (Int J Dermatol)
✓ PubMed
Double-blind RCT (n=46) comparing topical+oral glutathione combination vs monotherapy over 8 weeks: combination group had significantly lower melanin index and L* score vs placebo (p<0.05) and the largest mean change of all groups, indicating combined oral+topical glutathione may be superior to monotherapy as a skin-whitening agent.
rct
Weschawalit 2017 (RCT)
✓ PubMed
Randomized, double-blind, placebo-controlled three-arm trial in healthy women taking oral reduced glutathione (GSH) 250 mg/day, oxidized glutathione (GSSG) 250 mg/day, or placebo for 12 weeks; melanin index and UV spots trended lower than placebo at all sites, GSH significantly reduced wrinkles at some sites, with no serious adverse effects.
RCT
Arjinpathana & Asawanonda 2010 (RCT)
✓ PubMed
Double-blind RCT of oral glutathione 500 mg/day vs placebo for 4 weeks (60 adults); melanin index fell at all sites, reaching significance at 2 of 6 sites — modest, short-term lightening.
RCT
Weschawalit / Indonesian multicenter RCT
✓ Full text
Indonesian multicenter randomized controlled trial of oral glutathione combined with ascorbic acid, alpha-lipoic acid, and zinc aspartate reported significant reduction in melanin index as a skin-lightening agent versus comparator, with good tolerability.
narrative review
Alzahrani 2025 (narrative review)
✓ PubMed
Narrative review concluding glutathione shows depigmenting potential across oral, topical, and IV routes but evidence is limited; warns intravenous use carries serious risks (anaphylaxis, hepatotoxicity) and urges caution pending large rigorous trials.
Review
Narrative review of safety/efficacy 2025
✓ Full text
Narrative review concluded that while oral and topical glutathione may give modest, localized lightening, intravenous glutathione for skin lightening has no published efficacy trials and is associated with serious risks including anaphylaxis and hepatotoxicity without standardized dosing.
Review
Sitohang & Ninditya 2020 (Dermatol Res Pract)
✓ PubMed
Evidence-based review of 3 RCTs of systemic glutathione for skin whitening: one trial found no benefit, two showed significant effects only in certain body sites or age groups, with no long-lasting effect; oral preparations were well tolerated whereas parenteral were not. Concluded systemic glutathione is not sufficiently beneficial as a whitening agent.
Review
Sonthalia 2016 (review)
✓ PubMed
Critical review concluding antimelanogenic activity is plausible but clinical evidence is limited, with no evidence supporting intravenous glutathione for whitening.
case-series
Johnstone 2018 (case series)
✓ PubMed
Case series in Epidemiology and Infection documenting seven patients with probable endotoxin poisoning after intravenous glutathione infusions; all infusion samples exceeded the maximum pyrogenic endotoxin threshold, producing fever, rigors, hypotension and other symptoms within 2 hours, underscoring contamination risks of compounded IV glutathione.